Tailoring Adjuvant Endocrine Therapy for Premenopausal Women

Absolute Improvements in Freedom from Distant Recurrence with Adjuvant Endocrine Therapies for Premenopausal Women with HR+/HER2- Breast Cancer, as Investigated in the TEXT and SOFT Clinical Trials, According to Composite Risk

This Website uses Cookies. If you continue to use the website, you are aware of the use of Cookies. For more information please read our Privacy Policy

  Getting started: We strongly advise reading our paper before using this application, which is freely available at the Journal of Clinical Oncology.


Characteristics








Composite risk

            

            
          

        

      

      

        

          

            Distribution of Composite Risks: 
            
          

          

            STEPP Analysis: 
            
          

        

        

          

            
Distribution of composite risks in the 4 cohorts defined by trial and chemotherapy decision

          

          

            
8-year freedom from distant recurrence across composite risks in the 4 cohorts defined by trial 
                       and chemotherapy decision

          

        

        

          

            
          

        

        

          

            

            

            

          

          

            

            

            

          

        

        

          

            
          

        

        

          

            

            

            

          

          

            

            

            

          

        

        

          

            
          

        

        

          

            

            

            

          

          

            

            

            

          

        

        

          

            
          

        

        

          

            

            

            

          

          

            

            

            

          

        

      

    

    

    

      

      IBCSG

      DFCI

      BCRF
      

      

        
      
Abbreviations

      

        TEXT = Tamoxifen and Exemestane Trial;  SOFT = Suppression of Ovarian Function Trial 

        HR+/HER2- = hormone receptor positive, HER2 negative;  ER = estrogen receptor;  PgR = progesterone receptor;  OFS = ovarian function suppression
      

    
      
More Information

      

        *  TEXT and SOFT are sponsored by the  International Breast 
        Cancer Study Group, in collaboration with many world-wide breast cancer cooperative groups.
        

        *  TEXT and SOFT results were first published in  2014 and  
        2015 after approximately 5 years median follow-up. The results were updated in 
         2018 after approximately 
        8-9 years median follow-up and are the basis for this analysis.
        

        *  Details of the analyses for this web application were published in the 
         Journal of Clinical Oncology.
        

        *  This web application was made possible by grants from the Friends of Dana-Farber Cancer Institute and the 
        Breast Cancer Research Foundation.
        

        *  This analysis uses the  
        STEPP function in R, as nicely described by  Lazar et al.
      

                        
      
Disclaimer

      

        While Dana-Farber Cancer Institute uses reasonable efforts to include accurate and up to date information in 
        the Site, it makes no warranties or representations with respect to the content of the Site, which is provided 
        "as is". Dana-Farber Cancer Institute and International Breast Cancer Study Group accept no responsibility or 
        liability whatsoever arising from or in any way connected with the use of this Site or its content. In particular, 
        Dana-Farber Cancer Institute and International Breast Cancer Study Group will not be liable for the accuracy, 
        completeness, adequacy, timeliness, or comprehensiveness of the information contained on the Site.
      

      
      
Contact

      

        If you have questions, you can contact us: ibcsg.statc@jimmy.harvard.edu. IBCSG Statistical Center, Department 
        of Data Sciences, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 USA.